TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study
While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.
You may also be interested in...
Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.
Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.
Nature Cell is set to begin a groundbreaking clinical trial in the US of a novel autologous stem cell therapy for Alzheimer's disease, a new approach likely to gain attention amid other high profile failures in the challenging indication.